On April 15, 2025, a news item published in The Economic Times titled "Sweet Surrender: Sanofi puts star insulin brand on block" reported that Sanofi India is in the process of selling its flagship insulin brand, Lantus, and mentioned Dr. Reddy's Laboratories Limited as one of the potential acquirers. This news has sparked discussions regarding Dr. Reddy's potential involvement in the acquisition of the Lantus brand.

In response to this media speculation, Dr. Reddy’s Laboratories has issued a statement under Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has made it clear that it does not comment on market speculations and emphasized that there is currently no event or information that necessitates a disclosure under the SEBI Listing Regulations.

Dr. Reddy’s Laboratories has always complied with Regulation 30 of SEBI, which requires companies to disclose material events or information promptly when they are considered significant enough to affect the financial standing of the company or its shareholders. The company maintains a commitment to transparency and ensuring that any material events or changes are disclosed to the relevant authorities and the public in a timely manner.

The speculation around the potential acquisition of Lantus by Dr. Reddy's comes in the wake of Sanofi India’s strategic move to divest the insulin brand. Lantus has been a major player in the diabetes treatment market globally, and its potential sale has attracted significant attention from various stakeholders in the pharmaceutical industry.

However, Dr. Reddy's Laboratories has clarified that, at present, no formal negotiations or definitive steps have been taken towards acquiring the brand. As such, there is no obligation for immediate disclosure under the SEBI regulations, and the company will only make such disclosures if any material information arises that requires it.

In addition to adhering to SEBI regulations, Dr. Reddy’s Laboratories emphasized that it will continue to monitor the situation closely and will make any necessary disclosures in accordance with applicable laws and regulations should new developments take place.

As of now, the company has no further comment on the matter, and any information concerning the acquisition will be disclosed to stakeholders as soon as it is deemed material. Dr. Reddy's Laboratories has reaffirmed its commitment to its shareholders, stakeholders, and the general public to provide prompt and accurate disclosures in the future.

In conclusion, Dr. Reddy’s Laboratories has responded to the speculation with transparency, assuring that there is no current information requiring disclosure under the SEBI regulations. The company continues to uphold the highest standards of compliance and corporate governance.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.